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Aristolochic acid (AA) is the major active component of medicinal plants from the Aristolochiaceae 
family of flowering plants widely utilized for medicinal purposes. However, the molecular 
mechanisms of AA systems effects remain poorly understood. Here, we employed a joint network 
analysis that combines network pharmacology, a protein–protein interaction (PPI) database, 
biological processes analysis and functional annotation analysis to explore system effects. Firstly, 
we selected 15 protein targets (14 genes) in the PubChem database as the potential target genes 
and used PPI knowledge to incorporate these genes into an AA-specific gene network that contains 
129 genes. Secondly, we performed biological processes analysis for these AA-related targets 
using ClueGO, some of new targeted genes were randomly selected and experimentally verified by 
employing the Quantitative Real-Time PCR assay for targeting the systems effects of AA in HK-2 
cells with observed dependency of concentration. Thirdly, the pathway-based functional enrichment 
analysis was manipulated using WebGestalt to identify the mostly significant pathways associated 
with AA. At last, we built an AA target pathway network of significant pathways to predict the 
system effects. Taken together, this joint network analysis revealed that the systematic regulatory 
effects of AA on multidimensional pathways involving both therapeutic action and toxicity.
Aristolochic acid (AA) is an active compound that is derived from medicinal plants of the Aristolochiaceae 
family and has been broadly utilised for medicinal purposes for thousands of years. AA is a mixture of 
structurally related nitrophenanthrene carboxylic acids, with aristolochic acid I (AAI) and aristolochic 
acid II (AAII) is regarded as the major active components of AA1. The AA-containing drugs derived from 
these medicinal plants are often used in obstetrics and for treating snake bites, cancer, microorganisms, 
type B hepatitis, inflammation, arthritis and rheumatism1–5. However, AA has been also identified as a 
strong cytotoxic nephrotoxin and carcinogen in terms of its toxicity to complex systems, thus limiting 
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its clinical application and resulting in severe host side effects termed as aristolochic acid nephropathy 
(AAN), which is a chronic, fibrosing, interstitial nephritis disease1,6. AAN was first reported in Belgium 
in 1993, and soon afterwards, similar cases were found in Asia and in other European countries2,7–9. A 
high risk of urothelial cancer was also diagnosed with AAN patients2,10. Some reports have indicated 
that AA exposure is the primary cause of AAN and Balkan endemic nephropathy, which results in the 
formation of specific AA-DNA adducts and in the mutation and overexpression of TP53, affecting the 
development of AAN-associated urothelial cancer11,12. AA is also known to be a potent mutagen and car-
cinogen, being among the most potent 2% of carcinogens13. Thus, herbal remedies containing AA have 
been classified as human carcinogens by the International Agency for Research on Cancer (IARC)14. In 
wide-range clinical trials, AA primarily induced multiple carcinomas, which were found in the stomach, 
liver, kidney, bladder, lung, skin and other organs. Due to the nephrotoxic and carcinogenic effects of 
AA, many associated pharmaceutical products have been banned in many Western countries. Moreover, 
AA further contributes to multiple forms of toxicity such as renal tubular epithelial cell degeneration, 
necrosis, apoptosis, dysregulated prostaglandin metabolism, genotoxic, and reproductive toxicity because 
of its bioactivities and reactions with cellular proteins and DNA15–18. However, the toxicological targets 
and associated molecular mechanisms of AA remain unclear. Currently, a comprehensive method that 
can identify the targets of AA toxicity and effects, more importantly, that can explore relevant toxicolog-
ical and therapeutic mechanisms of AA is necessary.
In recent years, network pharmacology, a systems biology-based methodology, has been utilised 
extensively for the study of traditional Chinese medicine (TCM)19,20. A newly emerged “TCM network 
pharmacology approach” derived from network pharmacology is providing a new opportunity for trans-
lating TCM from an experience-based medicine into an evidence-based medicine system, quickening 
TCM-based drug discovery, and enhancing current strategies for drug discovery21,22. The TCM network 
pharmacology approach is being broadly explored and exploited for the study of single herbs, medicine 
pairs, and TCM formulas23 by coordinating with the conventionally experimental methods. For example, 
Li et al.24, efficiently applied this approach to identify molecular targets and to determine the pharma-
cological mechanisms of a typical traditional Chinese medicine formula, Liu Wei Di Huang (LWDH). 
Moreover, network pharmacology strategy emphasises maximising drug efficacy and minimising drug 
side effects by targeting multiple channels of the signalling pathway25–27. This approach focuses on the 
toxic reaction of a specific component in a complex system and offers assistance for drug safety assess-
ment28. Fan et al.29 reconstructed the network model to describe toxicological properties using the net-
work pharmacology method, which provides a wealth of information for screening toxic substances and 
for determining the potential toxicity of known compounds in a complex biological system. Therefore, 
to the best of our knowledge, network pharmacology is supposed to be a promising method for better 
understanding the systems effects (systems toxicity) of AA against the biological systems.
In this study, we attempted to clarify AA toxicity and associated biochemical actions by employing 
network pharmacology method as a joint network analysis was employed for the first instance that 
effectively combined network pharmacology, a protein–protein interaction (PPI) database and functional 
annotation analysis to clarify.
Materials and Methods
The standard flowchart this study is illustrated in Fig.  1, as we employed a joint network analysis that 
combines network pharmacology, a protein–protein interaction (PPI) database, biological processes anal-
ysis and functional annotation analysis to explore system effects. Firstly, we selected 15 protein targets 
(14 genes) in the PubChem database as the potential target genes and used PPI knowledge to incorporate 
these genes into an AA-specific gene network that contains 129 genes. Secondly, we performed biological 
processes analysis for these AA-related targets using ClueGO, 13 of new identified genes were randomly 
selected and experimentally verified by employing the Quantitative Real-Time PCR assay for the first 
time that noticeably characterized the systems effects of AA in HK-2 cells with observed dependence of 
concentration. Thirdly, the pathway-based functional enrichment analyses was manipulated by adopting 
WebGestalt to identify the mostly significant pathways associated with AA. At last, we built an AA target 
pathway network of significant pathways to predict and characterise the system effects.
Retrieval of candidate protein targets. First, potential protein targets and their interaction pro-
teins were retrieved from two independent sources, i.e., the PubChem and STRING databases, respec-
tively. PubChem (https://pubchem.ncbi.nlm.nih.gov/)30 is a public repository of small molecules and 
their biological properties, with more than 25 million unique chemical structures and 90 million bio-
activity outcomes associated with several thousand macromolecular targets. The search for candidate 
protein target was manipulated using “aristolochic acid” as the query keyword, and a list of protein tar-
gets was generated. This initial protein target list was prioritised based on different species and different 
active compounds against the protein targets. We selected protein targets from Homo sapiens with active 
compounds ≥ 1 and acquired a shortlist of potential protein targets.
Second, the shortlist of potential protein targets, Table 1, was used as the seed to search for direct and 
indirect interacting proteins by subjecting this list to STRING 9.1 database searches31. STRING is a data-
base that is composed of the known and predicted relationships of protein interactions and that provides 
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a wealth of biochemical information from widely different sources regarding their neighbourhood, gene 
fusion, co-occurrence, co-expression, experiments, database and literature mining.
Finally, for each seed target, we aimed at determining its direct interacting protein as a candidate 
protein target. Let S be defined as a set that contains all seed targets and their direct interacting proteins. 
Here, we employed STRING to predict interactions between and among seed targets and their direct 
interacting proteins in S.
Network construction of AA targets. Firstly, we combined all potential protein targets and candi-
date protein targets to construct an AA-specific gene network. Secondly, this gene network was further 
visualised using Cytoscape v 2.8.2 software32. Notably, we adopted the STRING database to predict inter-
actions between potential protein targets and interactions among candidate protein targets.
Functional annotation of AA-related targets. Biological processes analysis. To further under-
stand the biological relevance of the characterized targets related to AA, we performed biological pro-
cesses analysis using ClueGO33. The Cytoscape plug-in ClueGO is a professional software that was widely 
employed to facilitating the visualisation of functionally related genes, which are characterized and dis-
played as a clustered network and as a statistical chart as the ClueGO setting term: “Biological processes” 
was selected in this analysis. The statistical test used for the enrichment was based on a two-sided hyper-
geometric option with a Bonferroni correction, a P-value less than 0.001 and a kappa score of 0.35. In 
addition, the medium network type was selected as well. To establish the annotation network, functional 
groups were visualised in the network via ClueGO assay, which primarily adopted the organic layout 
algorithm.
Network mode construction of AA target pathways. We performed the pathway-based functional enrichment 
analyses using WebGestalt (Web-based Gene Set Analysis Toolkit, http://genereg.ornl.gov/webgestalt)34. 
A P-value less than 0.05 was considered the cut-off criterion. WebGestalt is a system that facilitates 
the analysis of sets of genes that can be visualised and organised by a user-selected method (e.g., Gene 
Figure 1. Schematic illustration of the standard workflow utilized in this study. This workflow is 
composed of the following four steps. 1) Retrieve protein targets from the PubChem database and their 
interaction proteins from the STRING database. 2) Visualise the AA-specific gene network (APN) using 
Cytoscape v 2.8.2. 3) Validate the genes associated with AA through literature retrieval, network analyses 
and experimental verification. 4) Engage in functional enrichment analysis of biological processes (BPs) and 
pathway analysis.
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Ontology, KEGG Pathway), and different annotations can be selected and retrieved for each set. Here, 
we constructed an AA target pathway network by connecting AA, predicted targets and their pathways. 
At last, the AA target pathway network was visualised using Cytoscape v 2.8.2.
HK-2 cells exposure to AAI treatment. HK-2 cell was originally purchased from (ATCC, USA) and 
maintained in DMEM/F-12 at 37 °C with 5% CO2, cells were seeded in 10 mm dishes at a density of 
approximate 1 × 107 cells per dish and then incubated for 12 h either without or with AAI at various 
concentrations as 10 mM, 50 mM and 100 mM, respectively.
Quantitative Real-Time PCR assay of the selected gene expressions in HK-2 cells treated by AA. Real-time 
PCR assay was carried out as the standard protocol reported by Mouritzen et al. (Mouritzen et al., 
2005) with minor modifications. Total RNAs were isolated from Human’s HK-2 cells using TRIZOL 
Reagent (Invitrogen Cat.No.15596-026) by referring to the manufacturer’s instruction. The QuantiTect 
RT Reverse Transcription Kit (Takera: Cat. No.RR047A) was utilized for cDNA amplification by accord-
ing to the manufacturer’s protocol. The Real-time PCR Kit (Takera SYBR Premix Ex Taq  II  Cat. No. 
RR820A) was used to facilitate the sequence amplification by following the manufacturer’s guideline. 
To analyze the relative abundance of transcripts using quantitative RT-PCR, HK-2 cells were seeded in 
10 mm dishes at a density of 1 × 107 cells per dish to isolated RNA.1ug total RNA was reverse transcribed 
for 15 min at 37 °C to attain 20ul cDNA. Quantitative RT-PCR was performed in optical 96-well plates 
using Roche Light Cycle 96 three step Real-Time PCR systems (n = 3, triplicate repetition). Reactions 
were performed in a final volume of 25 μ L containing 12.5 μ L of SYBR premix Ex Taq II, 2 mMof each 
primer, and 10 ng of cDNA. PCR conditions were set as 95 °C for 30 s, followed by 45 cycles of 95 °C for 
5 s and 60 °C for 30 s, 72 °C for 30 s. Fluorescence threshold data (Ct) was analyzed using Light Cycle 96 
system software, then exported to Microsoft Excel for further plotting and visualization. Relative expres-
sional levels in each cDNA sample were normalized to a NAPDH gene. In this study, the primer of each 
gene were designed using Primer 5 software. The sequence details were listed in Table 2. NAPDH gene 
was adopted as an internal control and to assess the efficiency of cDNA synthesis. Quantitative data was 
representative of the triplicate experiments.
Results and Discussion
Construction of an AA-specific gene network. We retrieved 15 potential protein targets (14 tar-
get genes) from the PubChem database (see Table  1) and 115 candidate protein targets (target genes) 
from the STRING database. The 129 genes were globally evaluated using the STRING database to 
characterise the interactions among them. As a result, an AA-specific protein network was constructed 
using the STRING database and then visualised using Cytoscape. This network involved 129 gene and 
1250 interactions (Fig. 2). All genes in this network can be either directly or indirectly associated with 
AA according to literature retrieval and relevant network analyses.
Among the 129 genes involving potential protein targets of AA, 12.4% have a direct relationship 
with AA that was reported by previous studies. For example, TP53, a tumour suppressor gene, plays a 
pathogenic role in acute AAN, and p53 protein overexpression is closely linked to urothelial carcinomas 
No Protein Targets Gene Symbol
1 oestrogen nuclear receptor alpha ESR1
2 glucocorticoid receptor NR3C1
3 cellular tumour antigen p53 TP53
4 sentrin-specific protease 8 SENP8
5 nuclear factor erythroid 2-related factor 2 isoform 2 NFE2L2
6 peroxisome proliferator-activated receptor gamma PPARG
7 peroxisome proliferator-activated receptor delta PPARD
8 putative hexokinase HKDC1 HKDC1
9 AR protein cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA a AR
10 cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CYP19A1
11 microtubule-associated protein tau MAPT
12 TDP1 protein TDP1
13 cytochrome P450 1A2 CYP1A2
14 nuclear factor erythroid 2-related factor 2 isoform 1 NFE2L2
15 interleukin-1 beta proprotein IL1B
Table 1.  Fifteen protein targets associated with AA.
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and urothelial atypia in patients with AAN35,36. Moreover, STAT3, which is a signal transducer and tran-
scription activator, also plays important roles in many cellular processes such as cell growth and apop-
tosis37,38. A study reported that AA induces TEC death via apoptosis by STAT3 dephosphorylation and 
by posttranslational p53 activation39. MDM2, a target gene of the transcription factor p53, is involved in 
cell cycle regulation40. Chen et al.41 and Volker et al.42 demonstrated MDM2 is significantly downregu-
lated by AA treatment. NQO1 (NAD(P) quinone oxidoreductase), which is an AA-activating enzyme, 
might play a key role in cancer susceptibility due to AA exposure. In addition, Katerina et al.43 and Bárta 
et al.44 suggested that AAI can augment its own metabolic activation by inducing NQO1, thus heighten-
ing its own genotoxic potential. Also, BRCA1 is a known tumour suppressor. BRCA1 and/or p53 mod-
ulate AAI-induced genes involved in DNA damage and cell cycle regulation in renal tubular epithelial 
cells in vitro, and several important targets for prostate cancer are modulated by BRCA1 and p5345,46.
Moreover, 40% of the identified target genes are involved in many important mechanisms of action 
associated with AA. For examples, ATM, which is a regulator of p53 and BRCA1, also functionalizes as 
a pro-apoptotic gene involved in urothelial cancer cell apoptosis47,48. C12orf5 (TIGAR) is a p53-inducible 
gene that basically regulates glycolysis and apoptosis49. TIGAR increases NADPH production so as to 
limit the generation of reactive oxygen species (ROS) by beneficially modulating the pentose phosphate 
pathway50. TIGAR protein expression also protects cells from ROS-induced DNA damage and provides 
protection against DNA damage-induced apoptosis51,52. APOE, a lipid metabolism-related gene, is a pro-
tective factor for renal diseases53. These genes may be involved in many important therapeutic actions 
Gene Symbol Primer F Primer R
AR 5′ -GCCTGGCTTCCGCAACTTACAC-3′ 5′ -GCGAAGTAGAGCATCCTGGAGT-3′ 
C11ORF17 5′ -CCCCAACCCTTAGTGCTTCCTTC-3′ 5′ -GCTTCGACTCGCCTCTGTGATA-3′ 
CDK5 5′ -CAATGGTGACCTCGATCCTGAG-3′ 5′ -CCTGTTTATTAGCGGGTTCTGG-3′ 
CDKN1A 5′ -TCACCGAGACACCACTGGAGGG-3′ 5′ -CCTGAGCGAGGCACAAGGGTAC-3′ 
CYP19A1 5′ -TTTTGGAAATGCTGAACCCGATAC-3′ 5′ -GTAGTTGCAGGCACTGCCGATC-3′ 
ESR 5′ -CATGAAGTGCAAGAACGTGGTG-3′ 5′ -AAGGAATGCGATGAAGTAGAGCC-3′ 
ESRRA 5′ -GTGGGCGGCAGAAGTACAAG-3′ 5′ -TCGGTCAAAGAGGTCACAGAGGGT-3′ 
ILI8 5′ -TAAAGATAGCCAGCCTAGAGGTAT-3′ 5′ -TGTTATCAGGAGGATTCATTTC-3′ 
IL1R1 5′ -ATACTTGGGCAAGCAATATCCT-3′ 5′ -TGTCTCATTAGCTGGGCTCACA-3′ 
IL1RAP 5′ -CTCTGACTGTAAAGGTAGTAGGCTCT-3′ 5′ -TTCCATCAATGGTCCACCAAAC
IL23A 5′ -TCTGCTCCCTGATAGCCCTGTG-3′ 5′ -CTTGGAATCTGCTGAGTCTCC-3′ 
IL4 5′ -TTCTCTGCTCCCTGATAGCC-3′ 5′ -CTTGGAATCTGCTGAGTCT-3′ 
JUN 5′ -CGGTCTACGCAAACCTCAGCAACT-3′ 5′ -TGATCCGCTCCTGGGACTCCAT-3′ 
GAPDH 5′ -TCCCTGAGCTGAACGGGAAG-3′ 5′ -GGAGGAGTGGGTGTCGCTGT-3′ 
Table 2.  Primer sequence for the targeted genes expressed in HK-2 cells.
Figure 2. AA-specific protein network. Green denotes genes that can directly associate with AA. Pink 
denotes genes that can indirectly associate with AA.
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that indirectly correlate with AA, involving anti-inflammation, anti-cancer, anti-microorganism, apop-
totic and fibrotic effects.
Other identified genes might indirectly contribute to the better understanding of system effects of 
AA. For example, Cdk5 is a mediator of neuronal death and the DNA damage response54. LIG1 muta-
tions lead to immunodeficiency and to increased sensitivity to DNA-damaging agents55. MED1 regulates 
p53-dependent apoptosis and is essential for adipogenesis56. AA induces DNA damage, TP53 mutation 
or overexpression, and apoptosis and inhibits adipose accumulation57. However, there was no present 
evidence to manifest if those identified genes are actually correlated with systems effects of AA involving 
therapeutic actions and tissue toxicities.
To validate the predictive efficiency of the adopted joint network approach to the non-evident genes, 
we further treated the HK-2 cells with AAI in a variety of concentrations as 10 mM, 50 mM and 100 mM, 
respectively, then Quantitative Real-Time PCR assay was employed for the determination of relative 
expressional levels of 13 identified genes without direct evidence to link to the systems effects of AA 
against HK-2 cells, they are C11ORF17, IL1RAP, JUN, CYP19A1, IL4, IL23, ESR1, AR, IL1R1, ESRRA, 
CDKN1A, CDK5 and ILI8 (see Table 2). The results demonstrated that the normal expressional levels of 
the selected genes were significantly perturbed by AAI treatment in HK-2 cells, but not the IL1R1, CDK5 
genes (see Figs  3 and 4). C11ORF17 and IL1RAP were down-regulated considerably when HK-2 cells 
exposed to AAI, however JUN, CYP19A1, IL4, HIL23A and ESR1 were observably upregulated by AAI. 
Interestingly those gene expressions were perturbed by AAI treatment rendered a remarkable dependent 
of concentration (Fig. 3). Contrast to the linear modulation of those identified genes by AAI interven-
tion, the others including AR, ESRRA, CDKN1A and ILI8 were perturbed markedly by AAI treatment as 
well, while the expressional changes were not characterized as the noticeable dependent of concentration 
(Fig.  4). Take altogether, most of those selected genes were modulated significantly by AAI treatment 
that is consistent with our predictive results by the joint network approach as an experimental evidence 
confirmed and validated that this adopted network biology approach was feasible and confident, it holds 
the capacity to efficiently discovery and identify the candidate genes implicated in the defined biolog-
ical events such as drug toxicity, drug effects or even disease development, which might provide novel 
insights into those biological events by integrating with relevantly experimental verification.
Biological annotation of AA-related targets. Analysis of biological processes. To annotate the bio-
logical functions of AA-related targets, we manipulated the functional enrichment analyses using Gene 
Ontology (GO) terms and further evaluated the biological processes (BPs) term using the Cytoscape 
plug-in ClueGO. Overall, 178 GO terms were significantly enriched, as shown in Fig.  5A. These GO 
terms have been categorised into 21 sub-groups, as shown in Fig.  5B, which primarily involve in liver 
development, positive regulation of apoptotic process, and cell-type specific apoptotic process.
Many key processes and key factors affected by AA were highlighted by the BP enrichment analy-
ses. We identified the following BPs associated with AA-related targets and their involvement: positive/
negative regulation of apoptotic process, negative regulation of programmed cell death, steroid meta-
bolic, liver development, and cellular hormone metabolic. Numerous studies have demonstrated that AA 
affected these biological processes. Apoptosis is a biological process that responds to toxicity-induced 
DNA damage. AA exposure induced apoptotic activities in cell culture and in kidney tubular epithelial 
cells58,59. Apoptosis is considered as the primary mechanism involved in the development of AAN. AA 
also induces TEC death via apoptosis in acute AAN by targeting the p53 signalling pathway; AA has 
also been observed to trigger STAT3 dephosphorylation and p53 activation to mediate TEC death via 
the apoptosis mechanism in acute AAN60,61. While AA can influence steroid and lipid metabolism in 
the liver58 as it inhibits phospholipase A2, which can form fatty acid and lysophospholipid products by 
hydrolysing phospholipids62. AA can significantly inhibit triglyceride accumulation, decrease total cho-
lesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations in the blood, and induce 
low PPARG (PPAR-γ ) expression57. These differential biological processes enable us to better understand 
of the toxicological and pharmacological effects of AA.
Schematic construction of an AA target pathway network. To better understand the biological functions 
of AA-related targets, we carried out pathway-based functional enrichment analyses via WebGestalt. 
Ninety-one genes were significantly enriched, and 79 significant pathways with cut off P-values <0.05 
were systematically enriched. Collectively, an AA target pathway network was constructed in Cytoscape 
that included 171 nodes and 1299 edges (Fig.  6). Furthermore, the AA target pathway network was 
divided into approximately 6 parts according to the pathway information.
AA causes renal toxicity. Previous studies have demonstrated that AA and its derivatives can affect renal 
physiological processes by perturbing many molecular pathways, including signal transduction pathways, 
which lead to the occurrence of tissue toxicity. AA-related targets mostly involved in numerous biological 
functions that basically accounted for the different stages of renal toxicity. These biochemical functions 
primarily include AA metabolism, the cell cycle, and the apoptosis pathway as AA induced apoptosis 
in renal tubular epithelial cells and AAI induced DNA damage and cell cycle arrest in renal tubular 
epithelial cells through targeting a wild-type p53-independent pathway63–65. Here, our investigation of 
the molecular mechanisms of AA-induced toxicity may explain why apoptosis or limited proliferation 
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and regeneration, the clinical manifestations of AA-associated nephrotoxicity, were induced in tubular 
epithelial cells.
Many studies have suggested that AA upregulates TGF-β expression, which may account for the 
development of AAN, and that AA can activate the Smad3 signalling pathway to mediate renal fibrosis 
by targeting both the TGF-β pathway and the JNK/MAP kinase-dependent pathway66,67. These studies 
suggested that the TGF-β /Smad3 signalling pathway may be a novel therapeutic target for chronic AAN.
In addition, as we known that xenobiotic metabolism is associated with the cytochrome P450 meta-
bolic pathway. A line of studies have illustrated that cytochrome P450 (CPY) enzymes mediate the for-
mation of AA-DNA adducts, that the role of this pathway in AAI metabolism in vivo has been validated, 
and that CPY1A1 and CPY1A2 are involved in the detoxification of carcinogenic AA68–70. Herein, AA 
mostly probably affect cytochrome P450 and drug metabolic pathways during the development of renal 
injury and cancer. Furthermore, AA also exerts substantial influences on some carbohydrate metabolic 
Figure 3. AAI treatment remarkable regulated the gene expressions with a remarkable concentration 
dependent in HK-2 cells. AAI-0: HK-2 cells without AAI treatment; AAI-1: HK-2 cells were treated with 
AAI (10 mM); AAI-2: HK-2 cells were treated with AAI (50 mM); AAI-3: HK-2 cells were treated with AAI 
(100 mM). Compared to AAS-0 (control group), it was considered as statistical difference while P value is less 
than 0.05 (*), and it was considered as significantly statistical difference when P value is less than 0.01 (**).
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pathways such as galactose metabolism, fructose and mannose metabolism. Chen et al.5 have confirmed 
that AA induces remarkable alterations in carbohydrate metabolism in HK-2 cells. Thus, these carbohy-
drate metabolic pathways further suggested that AA can induce nephrotoxicity.
Anti-inflammatory function of AA. Inflammatory processes are often induced by the actions of 
pro-inflammatory cytokines, including NFKB1, NFKB3, IL1B, IL18, and IL6, and are resolved 
by anti-inflammatory cytokines such as IL4 and IL1R2. JAK-STAT signalling can be activated by 
unregulated cytokines and by cytokine/receptor interactions (JAK-STAT signalling is involved 
in cyclophosphamide-induced bladder inflammation in female rats). This evidence demonstrates 
that chronic AAN inflammation can be identified by T cell and macrophage infiltration and by 
pro-inflammatory chemokine/cytokine upregulation, accompanied by RELA (NFKB3/p65) activation71 
(NFKB1 and RELA (NFKB3/65) encode the major component of the NF-κ B complex). Chen et al.5 
demonstrated that AA can suppress NF-κ B activity in human cells, which partly explained the toxico-
logical and anti-inflammatory effects of AA. Toll-like receptors (TLRs) are the primary constituents of 
the innate immune system that activate inflammatory signalling, including NF-kB activation, which can 
activate NF-κ B via a MyD88-dependent signalling pathway72,73. Moreover, the Wnt signalling pathway 
participates in many inflammatory responses. Wnt acts via the TLR/NF-κ B signalling pathway to upreg-
ulate pro-inflammatory genes74. Wnt also plays a vital role in the AA-induced epithelial to mesenchymal 
transition (EMT). Moreover, the TLR, NF-κ B and Jak/STAT signalling pathways are involved in renal 
inflammation as well75. NF-κ B may expand the inflammatory response and plays a core role in renal 
inflammation.
Figure 4. AAI treatment regulated the gene expressions in a variety of manners in HK-2 cells. AAI-0: 
HK-2 cells without AAI treatment; AAI-1: HK-2 cells were treated with AAI (10 mM); AAI-2: HK-2 cells 
were treated with AAI (50 mM); AAI-3: HK-2 cells were treated with AAI (100 mM). Compared to AAS-0 
(control group), it was considered as statistical difference while P value is less than 0.05 (*), and it was 
considered as significantly statistical difference when P value is less than 0.01 (**).
www.nature.com/scientificreports/
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Carcinotoxicity of AA. The molecular mechanism of AA-induced cancer provides a strong association 
between DNA adducts, p53 mutations and tumour development2. Schmeiser et al.76 revealed that the 
long-term oral administration of AAI to male Wistar rats has been observed to induce the tumours in 
multiple organs as they found manifested that AAI induced pancreatic cancer, renal cell carcinoma, lung 
cancer and other cancers, suggesting that AA-DNA adducts are critical lesions for tumour development. 
AA-induced A:T-to-T:A transversions are considered as the primary cause of bladder cancer77. The ras 
gene family is primarily involved in cell growth and cell differentiation, and activated ras genes are 
expressed in colorectal cancer, pancreatic tumours, and thyroid tumours. It was reported that aristolochic 
Figure 5. Network groupings based on functionally enriched BP terms. (A) A functionally grouped 
network of enriched categories was generated for AA-related targets using GO terms as nodes and linked 
using ClueGO analysis. Only the most significant terms in the group are labelled. Functionally related 
groups partially overlap. (B) Functional groups and their corresponding colours.
www.nature.com/scientificreports/
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acid activates ras genes in rat tumours78; whereas AA-mediated induction of colorectal cancers and thy-
roid tumours may occur by targeting H-ras mutagenic activity.
Anti-microorganism activity of AA. AA inhibits the Ca2+- and heat shock-induced transformation of 
Escherichia coli with plasmid DNA79. Kevekordes et al. also confirmed that AA is capable of suppressing 
E. coli growth80. Hepatitis C virus (HCV) exposure often leads to severe liver diseases and that p53 is 
involved in the inhibition of HCV replication in hepatocytes81. AA can induce TP53 overexpression that 
often results in the inhibition of HCV replication. In addition, Helicobacter pylori infection induces IL1B 
expression and NF-κ B activation in gastric epithelial cells82, it suggested that AA may inhibit Helicobacter 
pylori infection in gastric epithelial cells by blocking NF-κ B pathways.
Novel biological functions of AA. As a TCM, AA has been broadly utilised for treating many inflamma-
tory diseases such as rheumatoid arthritis. Inflammatory reactions play significant roles in the progres-
sive deterioration observed in Alzheimer’s disease (AD), and NF-κ B is the first gene in the inflammation 
signalling pathway83. Recent studies have demonstrated that the dysregulation of the NF-κ B pathway 
induces low HTT expression, which is usually caused by Huntington’s disease (HD) immune dysfunc-
tion, and the p65 (RELA/NFKB3)-mediated inflammatory response in astrocytes plays a key role in 
HD84,85. Therefore, AA is able to suppress NF-κ B activity, which partly clarified the mechanism by which 
AA holds the capacity to treat AD and HD. Moreover, we also speculated that AA may treat parasitic 
diseases such as malaria86, Chagas disease, leishmaniasis, amoebiasis, toxoplasmosis, and African trypa-
nosomiasis, as well as other diseases such as graft-versus-host disease and prion diseases in terms of its 
functions with targeting multiple pathways.
Furthermore, we discovered several meaningful pathways related to AA functions that have scarcely 
been investigated before. These pathways may exert their joint efforts in supporting the system effects of 
AA in a variety of pathological contexts, such as the neurotrophin signalling pathway, haematopoietic 
cell lineage, caffeine metabolism, and osteoclast differentiation.
Conclusion
In the present study, we employed a joint network analysis that comprehensively combines network 
pharmacology, a protein-protein interaction (PPI) database and a functional annotation analysis to bet-
ter determine the system effects of AA in terms of tissue toxicity and therapeutic efficiency. The bio-
informatics screening of potential protein targets of AA identified a series of candidate protein targets, 
which were used to construct an AA-specific gene network. These genes are either directly or indirectly 
associated with AA as determined by literature retrieval and network analyses, furthermore some of new 
identified genes have been experimentally verified whose expression was significantly modulated by AA 
treatment with observed dependence of concentration, which basically argued that the developed joint 
network approach was feasible and robust with the applicable potential to predict the functions of the 
Figure 6. AA target pathway network mode. A red square denotes AA, blue circles denote genes, and 
green triangles denote KEGG pathways.
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known and unknown genes in the defined biological events/processes. Moreover, the biological process 
analysis demonstrated that AA may influence steroid and lipid metabolism, kidney tubular epithelial 
cells and the inflammatory response. Moreover, we constructed a novel modelling system by integrating 
multidimensional AA-related targets and pathway information. This system indicated that the multidi-
mensional regulatory effect of AA depended on the combined mechanisms involving nephrotoxicity, 
anti-inflammation, anti-cancer and anti-microorganism activities, and some other novel regulatory func-
tions. Take altogether, our results suggested that AA exerts multi-target toxicity and broad pharmacolog-
ical effects during intervening host-pathogen interactions.
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